Freenome Holdings, Inc. (“Freenome”) (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, announces the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (formerly Nasdaq: PCSC) (“PCSC”). The combined company will be renamed Freenome, Inc. and is expected to commence trading on the Nasdaq Capital Market on July 21, 2026, with its common stock trading under the new ticker symbol “FRNM”. The combined company is expected to have approximately $310 million in gross proceeds, consisting of approximately $70 million from the former PCSC trust account and a concurrent, fully committed $240 million private placement (PIPE).
Read the full article: Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection //
Source: https://www.globenewswire.com/news-release/2026/07/20/3330086/0/en/freenome-debuts-as-a-publicly-traded-company-focused-on-blood-based-early-cancer-detection.html?_gl=1*44ycxy*_up*MQ..*_ga*MTE3MDY1MjExNi4xNzg0NTg3MDY3*_ga_B6167QB2TF*czE3ODQ1ODcwNjckbzEkZzAkdDE3ODQ1ODcwNjckajYwJGwwJGgxMzA3NTY2NzQ2*_ga_ERWPGTJ5X8*czE3ODQ1ODcwNjckbzEkZzAkdDE3ODQ1ODcwNjckajYwJGwwJGgw